Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is SORAFENIB TOSYLATE 3, with a corresponding US DMF Number 34114.
Remarkably, this DMF maintains an Active status since its submission on September 30, 2019, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 05, 2019, and payment made on September 27, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II